New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites
Metadatos
Mostrar el registro completo del ítemEditorial
Frontiers Media
Materia
trypanosomatid parasites drug transport surface transporter
Fecha
2016-09-28Referencia bibliográfica
García Salcedo, J.A. et. al. Front. Pharmacol. 7:351. [https://doi.org/10.3389/fphar.2016.00351]
Patrocinador
JAGS was supported by “Programa Estatal de Investigación, Desarrollo e Innovación Orientada a los Retos de la Sociedad” (grant SAF-SAF2015-71714-RMINECO/FEDER); “Programa de Promoción de Empleo Joven e Implantación de la Garantía Juvenil en I+D+i”, MIMECO, SpainResumen
Leishmania and Trypanosoma are members of the Trypanosomatidae family that cause
severe human infections such as leishmaniasis, Chagas disease, and sleeping sickness
affecting millions of people worldwide. Despite efforts to eradicate them, migrations are
expanding these infections to developing countries. There are no vaccines available and
current treatments depend only on chemotherapy. Drug resistance is a major obstacle
for the treatment of these diseases given that existing drugs are old and limited, with
some having severe side effects. Most resistance mechanisms developed by these
parasites are related with a decreased uptake or increased efflux of the drug due to
mutations or altered expression of membrane transporters. Different new approaches
have been elaborated that can overcome these mechanisms of resistance including
the use of inhibitors of efflux pumps and drug carriers for both active and passive
targeting. Here we review new formulations that have been successfully applied to
circumvent resistance related to drug transporters, opening alternative ways to solve
drug resistance in protozoan parasitic diseases.